Abstract: Objective Hypertension is one of the most common adverse effects of bevacizumab,an inhibitor targeting vascular endothelial growth factors. It is widely used in the treatment of metastatic colorectal cancer. The relationship between bevacizumab-related hypertension（BAHT）and survival of patients with metastatic colorectal cancer was evaluated by meta-analysis. Methods PubMed,EMBASE,Cochrane Library,web of science,Wanfang,CNKI,VIP and CBM were searched,meta-analysis was then performed on sixteen published studies of bevacizumab in the treatment of metastatic colorectal cancer,primary endpoint was progression-free survival,overall survival and object response rate. Progression-free survival was defined as the interval between the beginning of bevacizumab treatment and clinical progression or death for any cause or the last follow-up（if no progress）,overall survival was defined as the interval between the beginning of bevacizumab treatment and death or the last follow-up,and objective response rate was defined as the ratio of the number of patients who responded completely or partially to the total number of patients evaluated. Hazard ratios（HR）for progression-free survival and overall survival were extracted from each trial,and the log of the relative risk ratio（RR）was estimated for object response rate.RevMan 5.3 was used for data analysis. Results BAHT was related to the increase of objective response rate（RR=3.49,95%CI 1.96-6.22,P＜0.001）and the improvement of progression-free survival（HR=0.68,95%CI 0.58-0.80,P＜0.001）and overall survival（HR=0.63,95% CI 0.53-0.75,P＜0.001）in metastatic colorectal cancer patients. Conclusion The occurrence of bevacizumab-related hypertension may associated with improved prognosis in patients with metastatic colorectal cancer.